Cholesterol drug pelacarsen fails to prevent heart attacks in major trial
Novartis' experimental cholesterol drug pelacarsen failed to reduce heart attacks or strokes in a major clinical trial, despite significantly lowering lipoprotein(a) levels. The Horizon trial, led by Dr. Steven Nissen, included 8,322 patients and found no cardiovascular health benefits. Experts express surprise and discuss potential reasons for the failure, while noting ongoing research into similar drugs by Eli Lilly, Amgen, and Silence Therapeutics.
How this was made
The 30-second read
Why it matters
The trial's neutral results undermine expectations for a new cardiovascular therapy and could lead to a re‑valuation of Novartis' pipeline.
Market read
First report of a major cardiovascular trial failure; likely to affect biotech valuations and investor sentiment toward Lp(a) therapeutics.
What to watch
Future trials of siRNA‑based Lp(a) drugs may still succeed; the failure may shift focus rather than halt the therapeutic class.
Background
Pelacarsen, an antisense oligonucleotide from Novartis, reduced Lp(a) levels by 78% but showed no clinical benefit in the Horizon trial of 8,322 high‑risk patients.
Ticker impact
Novartis' experimental cholesterol drug pelacarsen failed to reduce heart attacks or strokes in the Horizon trial, a first‑report clinical‑trial result.
downward pressure as the market prices in the lack of cardiovascular benefit.
First disclosure of a major Phase 3 failure for a high‑profile antisense therapy; analysts typically downgrade biotech stocks on such news.
Market effects
May dampen sentiment for antisense and siRNA cardiovascular programs across biotech sector.
Limited to US and European biotech equities; broader market impact minimal.
Highlights challenges in targeting lipoprotein(a), could affect global drug development pipelines.
Counterpoint
If pelacarsen's Lp(a) reduction is confirmed, a later indication could revive interest; short sellers may be premature.
Key entities
- companyNovartis
Developer of pelacarsen, a cholesterol‑lowering drug.
- companyEli Lilly
Developer of competing Lp(a) therapy lepodisiran.
